American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 27, Issue 2 , Pages 76-80 , March 2006

Decreased hearing after combined modality therapy for head and neck cancer

Received 4 March 2005

References 

  1. Browman GP, Hodson D, Mackenzie RJ, et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck. 2001;23:579–589
  2. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804
  3. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317
  4. Glicksman AS, Slotman G, Doolittle C, et al. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994;30(5):1043–1050
  5. Skinner R, Pearson AD, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61:927–931
  6. Sie KC, Norton SJ. Changes in otoacoustic emissions and auditory brain stem response after cis-platinum exposure in gerbils. Otolaryngol Head Neck Surg. 1997;116(6 Pt 1):585–592
  7. Morose M, Blair RJ. A review of cis-platinum ototoxicity. Otolaryngology. 1983;12:365–369
  8. Lauterman J, Song B, McLaren J, et al. Diet is a risk factor in cis-platinum ototoxicity. Hear Res. 1995;88:47–53
  9. Borsanyi S. The effect of radiation on the ear. South Med J. 1962;55:740–743
  10. Raaijmakers E, Engilen AM. Is sensorineural hearing loss a possible side effect of nasopharyngeal and parotid irradiation? A systematic review of the literature. Radiother Oncol. 2002;65:1–7
  11. Ho WK, Wei WI, Kwong DLW, et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck. 1999;21:547–553
  12. Honore HB, Bentzen SM, Moller K, et al. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol. 2002;65:9–16
  13. Douple E. Interactions between platinum coordination complexes and radiation. In: Antitumor drug radiation interactions. Boca Raton (Fla): CRC Press; 1990;p. 171–190
  14. Ondrey FG, Greig JR, Herscher L. Radiation dose to otologic structures during head and neck cancer radiation therapy. Laryngoscope. 2000;110(2 Pt 1):217–221
  15. Spoor A. Presbycusis values in relation to noise induced hearing loss. Audiol Int. 1967;9:48–57
  16. Schaefer S, Post J, Close L, et al. Ototoxicity of low and moderate dose cisplatin. Cancer. 1985;56:1934–1939
  17. Kopelman J, Budnick AS, Sessions RB, et al. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope. 1988;98:858–864
  18. Oh YT, Kim CH, Choi JH, et al. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol. 2004;72:79–82
  19. Kwong DL, Wei WI, Sham JS, et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys. 1996;36(2):281–289

PII: S0196-0709(05)00137-7

doi: 10.1016/j.amjoto.2005.07.008

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 27, Issue 2 , Pages 76-80 , March 2006

Article Tools

* Image Usage & Resolution